ClinicalTrials.gg

Program

opakalim

Its studies are mostly in Epilepsies, Partial · Depressive Disorder, Major · Bipolar Disorder · Neuralgia · Epilepsy, Idiopathic Generalized, led by Biohaven Therapeutics.

Furthest: phase 3, since Nov 10, 20239 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biohaven Therapeutics94 open or runningphase 3since Nov 10, 2023Nov 10, 2023Dec 2026phase 3 · NCT06132893

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 10, 2023First study: phase 3 study in Epilepsies, PartialFirst studyNCT06132893 · 390 enrolled · United States, Argentina, Austria and more
  2. Mar 8, 2024Phase 3 study in Epilepsies, PartialNCT06309966 · 390 enrolled · United States, Australia, Denmark and more
  3. May 14, 20244 phase 2 studiesNCT06419608, NCT06423794, NCT06423781 and 1 more
  4. May 14, 20242 phase 3 studiesNCT06419582, NCT06425159
  5. Nov 17, 2025Phase 1 study in ErythromelalgiaNCT07262268 · 5 enrolled · United States

Ahead

  1. Dec 2026Primary completion: phase 2 study in Epilepsies, PartialNCT06443463
  2. Dec 2026Primary completion: phase 3 study in Epilepsies, PartialNCT06132893
  3. Nov 2027Primary completion: phase 1 study in ErythromelalgiaNCT07262268

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07262268Erythromelalgia · United States1Active, not recruitingNov 20275
NCT06443463Epilepsies, Partial · United States, Argentina, Australia and more2By invitationDec 2026660
NCT06425159Epilepsy, Generalized · United States, Australia, Austria and more3TerminatedMar 12, 202627
NCT06423794Bipolar Disorder · United States2TerminatedApr 25, 202594
NCT06423781Depressive Disorder, Major · United States2CompletedMar 18, 2026233
NCT06419608Depressive Disorder, Major · United States2CompletedNov 7, 2025336
NCT06419582Bipolar Disorder · United States3CompletedJan 15, 2025274
NCT06309966Epilepsies, Partial · United States, Australia, Denmark and more3Active, not recruitingOct 2026390
NCT06132893Epilepsies, Partial · United States, Argentina, Austria and more3Active, not recruitingDec 2026390

How it is read

Names in the registry

  • “BHV-7000”, 13 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.